Please note: The information displayed on this page might be outdated.
Oculis Pharma: Developer of novel and transformative topical treatments (eye drops) intended for ophthalmic diseases for both back and front of the eye. The company's novel eye-drop treatments are based on its proprietary solubilizing nanoparticle (SNP) technology that improves both the ability to formulate drugs as eye drops and their bioavailability in the eye tissues including both the front and the back of the eye, enabling hospitals to provide clients with technological advancement in ocular drug delivery.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Ophthalmology, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology, Pharmaceuticals
Listing
Private
Market Cap
<100MM
Therapeutic Modalities
Antibodies
Website:
Profiles:
Address:
EPFL Innovation Park Building C
Lausanne, 1015
Switzerland

Company Participants at European Biotech Investor Day 2020

  • Riad Sherif, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.